Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Trump announces new pricing deals with midsize biotechs; Novartis pauses CAR-T trials ...

2 September 2026 · By · Wire by Fusion42

Published

2 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at raps.org →

◆ Verified

Fusion42 · 2 September 2026 · Fusion42 review

Former President Trump announced nine new drug pricing deals with midsize biotechs in the US, while Novartis paused CAR-T trials internationally after patient deaths.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face new US government pressure on drug pricing with deals now targeting midsize biotechs, shrinking your pricing flexibility this quarter. Novartis halting CAR-T trials signals heightened safety scrutiny that could delay your development timelines.

◆ Coverage

1 source · 2 Sep 2026

◆ Related on Wire

◆ Topics

Biotechdrug-pricingbiotechclinical-trialsregulationUSpharma